Basit öğe kaydını göster

dc.contributor.authorAggarwal, V.
dc.contributor.authorTuli, H.S.
dc.contributor.authorTania, M.
dc.contributor.authorSrivastava, S.
dc.contributor.authorRitzer, E.E.
dc.contributor.authorPandey, A.
dc.contributor.authorBishayee, A.
dc.date.accessioned2020-11-20T17:17:09Z
dc.date.available2020-11-20T17:17:09Z
dc.date.issued2020
dc.identifier.issn1044-579X
dc.identifier.urihttps://doi.org/10.1016/j.semcancer.2020.05.011
dc.identifier.urihttps://hdl.handle.net/20.500.12809/6283
dc.descriptionPubMed ID: 32461153en_US
dc.description.abstractEpigallocatechin gallate (EGCG), also known as epigallocatechin-3-gallate, is an ester of epigallocatechin and gallic acid. EGCG, abundantly found in tea, is a polyphenolic flavonoid that has the potential to affect human health and disease. EGCG interacts with various recognized cellular targets and inhibits cancer cell proliferation by inducing apoptosis and cell cycle arrest. In addition, scientific evidence has illustrated the promising role of EGCG in inhibiting tumor cell metastasis and angiogenesis. It has also been found that EGCG may reverse drug resistance of cancer cells and could be a promising candidate for synergism studies. The prospective importance of EGCG in cancer treatment is owed to its natural origin, safety, and low cost which presents it as an attractive target for further development of novel cancer therapeutics. A major challenge with EGCG is its low bioavailability which is being targeted for improvement by encapsulating EGCG in nano-sized vehicles for further delivery. However, there are major limitations of the studies on EGCG, including study design, experimental bias, and inconsistent results and reproducibility among different study cohorts. Additionally, it is important to identify specific EGCG pharmacological targets in the tumor-specific signaling pathways for development of novel combined therapeutic treatments with EGCG. The present review highlights the ongoing development to identify cellular and molecular targets of EGCG in cancer. Furthermore, the role of nanotechnology-mediated EGCG combinations and delivery systems will also be discussed. © 2020 Elsevier Ltden_US
dc.item-language.isoengen_US
dc.publisherAcademic Pressen_US
dc.item-rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCanceren_US
dc.subjectClinical studiesen_US
dc.subjectEpigallocatechin-3-gallateen_US
dc.subjectIn vitroen_US
dc.subjectIn vivoen_US
dc.subjectMolecular mechanismsen_US
dc.subjectTherapeutic targeten_US
dc.titleMolecular mechanisms of action of epigallocatechin gallate in cancer: Recent trends and advancementen_US
dc.item-typereviewen_US
dc.contributor.departmenten_US
dc.contributor.departmentTempAggarwal, V., Department of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab 160 012, India; Tuli, H.S., Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana–Ambala, Haryana 133 207, India; Tania, M., Division of Molecular Cancer, Red Green Research Center, Dhaka, 1205, Bangladesh; Srivastava, S., Department of Biotechnology, Motilal Nehru National Institute of Technology Allahabad, Prayagraj, Uttar Pradesh 211 004, India; Ritzer, E.E., Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, United States; Pandey, A., Department of Biotechnology, Motilal Nehru National Institute of Technology Allahabad, Prayagraj, Uttar Pradesh 211 004, India; Aggarwal, D., Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana–Ambala, Haryana 133 207, India; Barwal, T.S., Department of Zoology, Central University of Punjab, Bathinda, Punjab 151 001, India; Jain, A., Department of Zoology, Central University of Punjab, Bathinda, Punjab 151 001, India; Kaur, G., Department of Pharmacology, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, Mumbai, Maharastra 400 056, India; Sak, K., NGO Praeventio, Tartu, 50407, Estonia; Varol, M., Department of Molecular Biology and Genetics, Faculty of Science, Mugla Sitki Kocman University, Muğla, TR48000, Turkey; Bishayee, A., Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, United Statesen_US
dc.identifier.doi10.1016/j.semcancer.2020.05.011
dc.relation.journalSeminars in Cancer Biologyen_US
dc.relation.publicationcategoryDiğeren_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster